|
Neflamapimod
- 品牌：MedKoo
- 產(chǎn)地：美國(guó)
- 貨號(hào)：203163
- cas：209410-46-8
- 發(fā)布日期： 2022-07-20
- 更新日期： 2024-08-12
產(chǎn)品詳請(qǐng)
| 產(chǎn)地 | 美國(guó) |
| 品牌 | MedKoo |
| 貨號(hào) | 203163 |
| 用途 | This product is for research use only, not for human or veterinary use. |
| 包裝規(guī)格 | 10.0mg; 25.0mg; 50.0mg; 100.0mg; 200.0mg; 500.0mg; 1.0g; 2.0g; |
| CAS編號(hào) | 209410-46-8 |
| 純度 | >98%% |
| 是否進(jìn)口 | 是 |
中文名稱:5-(2,6-二氯苯基)-2-((2,4-二氟苯基)硫基)-6H-嘧啶并[1,6-b]噠嗪-6-酮
中文別名:VX-745游離態(tài)
CAS No:209410-46-8
分子式:C19H9Cl2F2N3OS
沸點(diǎn):578.9°Cat760mmHg
閃光點(diǎn):303.9°C
折射率:1.692
密度:1.55
用途:VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.
中文別名:VX-745游離態(tài)
CAS No:209410-46-8
分子式:C19H9Cl2F2N3OS
沸點(diǎn):578.9°Cat760mmHg
閃光點(diǎn):303.9°C
折射率:1.692
密度:1.55
用途:VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.
相關(guān)產(chǎn)品：
